464 Studies Now Enrolling
INTELLANCE 2: ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group
A study patients with recurrent glioblastoma using study drug ABT-414
| Sponsor: | AbbVie |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAQ7410 |
| U.S. Govt. ID: | NCT02343406 |
| Contact: | Ryan Shelton: 212-304-5485 / rs3233@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to test whether the new drug, ABT-414, given either alone or with a drug called temozolomide, which is commonly used to treat brain tumors like yours, gives a better outcome than the standard therapy and is safe. The standard therapy can be one of two different regimens, either a drug called lomustine or temozolomide.
This study is closed
